Clinical trialsCompany release
ALX Oncology reports $147.2M cash, with ALX2004 Phase 1 data due in December
🇺🇸 Alx Oncology Holdings Inc (ALXO) · Mon 16 Nov 2026
The US biotech posted a $21.8 million third-quarter net loss and says its cash runway extends into the first half of 2028.
ALX Oncology reported third-quarter 2026 results on 16 November, showing a net loss of $21.8 million. The company ended the period with $147.2 million in cash and investments, which it says is enough to fund operations into the first half of 2028.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Alx Oncology Holdings Inc ↗
Article written by VigiEye from the official source (Alx Oncology Holdings Inc). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ
🇺🇸 Cerenome, Inc. (CNSY) · Mon 16 Nov 2026
Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial
Clearmind Medicine Inc. (CMND) · Mon 16 Nov 2026
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 16 Nov 2026
CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer
🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026
Aptevo's mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall
🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 16 Nov 2026
Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF
🇺🇸 Rein Therapeutics, Inc. (RNTX) · Mon 16 Nov 2026